tiprankstipranks
Sangamo Therapeutics (DE:GBY)
MUNICH:GBY
Germany Market
GBY
Sangamo Therapeutics
RESEARCH TOOLSreports

Sangamo Therapeutics (GBY) Stock Forecast & Price Target

4 Followers
See the Price Targets and Ratings of:

GBY Analyst Ratings

Hold
1Ratings
Hold
0 Buy
1 Hold
0 Sell
Based on 1 analysts giving stock ratings to
Sangamo
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

GBY Stock 12 Month Forecast

Average Price Target

€1.76
▲(735.91% Upside)
Based on 1 Wall Street analysts offering 12 month price targets for Sangamo Therapeutics in the last 3 months. The average price target is €1.76 with a high forecast of €1.76 and a low forecast of €1.76. The average price target represents a 735.91% change from the last price of €0.21.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"€2","-1":"-€1","-0.25":"-€0.25","0.5":"€0.5","1.25":"€1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.75540842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€1.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.75540842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€1.76</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.75540842,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€1.76</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.066,0.19595449384615385,0.3259089876923077,0.4558634815384615,0.5858179753846153,0.7157724692307692,0.8457269630769231,0.975681456923077,1.1056359507692308,1.2355904446153847,1.3655449384615386,1.4954994323076924,1.625453926153846,{"y":1.75540842,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.066,0.19595449384615385,0.3259089876923077,0.4558634815384615,0.5858179753846153,0.7157724692307692,0.8457269630769231,0.975681456923077,1.1056359507692308,1.2355904446153847,1.3655449384615386,1.4954994323076924,1.625453926153846,{"y":1.75540842,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.066,0.19595449384615385,0.3259089876923077,0.4558634815384615,0.5858179753846153,0.7157724692307692,0.8457269630769231,0.975681456923077,1.1056359507692308,1.2355904446153847,1.3655449384615386,1.4954994323076924,1.625453926153846,{"y":1.75540842,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.415,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.457,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.464,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.435,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.561,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.486,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.381,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.346,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.439,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.318,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.178,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.052,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.066,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€1.76Average Price Target€1.76Lowest Price Target€1.76
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:GBY
Luca Issi
RBC Capital
RBC Capital
€1.76
Hold
735.91%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Sangamo Therapeutics (Other OTC: SGMO) and Insight Molecular Diagnostics (NASDAQ: IMDX)
Wells Fargo Analyst forecast on DE:GBY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€3.51→€1.76
Hold
735.91%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on DE:GBY
Gena Wang
Barclays
Barclays
€4.39→€0.88
Hold
317.95%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
TD Cowen Analyst forecast on DE:GBY
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/25
Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy Rating
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
RBC Capital Analyst forecast on DE:GBY
Luca Issi
RBC Capital
RBC Capital
€1.76
Hold
735.91%
Upside
Reiterated
05/14/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Aquestive Therapeutics (NASDAQ: AQST), Sangamo Therapeutics (Other OTC: SGMO) and Insight Molecular Diagnostics (NASDAQ: IMDX)
Wells Fargo Analyst forecast on DE:GBY
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
€3.51→€1.76
Hold
735.91%
Upside
Reiterated
01/05/26
Sangamo Biosciences (SGMO) Receives a Hold from Wells Fargo
Barclays Analyst forecast on DE:GBY
Gena Wang
Barclays
Barclays
€4.39→€0.88
Hold
317.95%
Upside
Downgraded
11/07/25
Sangamo Biosciences (SGMO) was downgraded to a Hold Rating at Barclays
TD Cowen Analyst forecast on DE:GBY
Ritu Baral
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/11/25
Sangamo Biosciences: Strategic Positioning and Growth Potential Drive Buy Rating
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Sangamo Therapeutics

3 Months
Ritu BaralTD Cowen
Success Rate
7/14 ratings generated profit
50%
Average Return
+10.88%
Copying Ritu Baral's trades and holding each position for 3 Months would result in 50.00% of your transactions generating a profit, with an average return of +10.88% per trade.
1 Year
OpenAI BiotechnologyTipRanks - OpenAI
Success Rate
1/4 ratings generated profit
25%
Average Return
+0.03%
Copying OpenAI Biotechnology's trades and holding each position for 1 Year would result in 25.00% of your transactions generating a profit, with an average return of +0.03% per trade.
2 Years
OpenAI BiotechnologyTipRanks - OpenAI
Success Rate
1/4 ratings generated profit
25%
Average Return
+0.03%
Copying OpenAI Biotechnology's trades and holding each position for 2 Years would result in 25.00% of your transactions generating a profit, with an average return of +0.03% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

GBY Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
1
2
4
4
3
Buy
0
0
0
0
0
Hold
1
2
1
2
3
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
2
4
5
6
6
In the current month, GBY has received 3 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. GBY average Analyst price target in the past 3 months is 1.76.
Each month's total comprises the sum of three months' worth of ratings.

GBY Financial Forecast

GBY Earnings Forecast

Next quarter’s earnings estimate for GBY is -€0.06 with a range of -€0.06 to -€0.06. The previous quarter’s EPS was -€0.07. GBY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GBY has Performed in-line its overall industry.
Next quarter’s earnings estimate for GBY is -€0.06 with a range of -€0.06 to -€0.06. The previous quarter’s EPS was -€0.07. GBY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year GBY has Performed in-line its overall industry.

GBY Sales Forecast

Next quarter’s sales forecast for GBY is €6.51M with a range of €6.51M to €6.51M. The previous quarter’s sales results were €1.25M. GBY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GBY has Performed in-line its overall industry.
Next quarter’s sales forecast for GBY is €6.51M with a range of €6.51M to €6.51M. The previous quarter’s sales results were €1.25M. GBY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year GBY has Performed in-line its overall industry.

GBY Stock Forecast FAQ

What is DE:GBY’s average 12-month price target, according to analysts?
Based on analyst ratings, Sangamo Therapeutics’s 12-month average price target is 1.76.
    What is DE:GBY’s upside potential, based on the analysts’ average price target?
    Sangamo Therapeutics has 735.91% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Sangamo Therapeutics a Buy, Sell or Hold?
          Sangamo Therapeutics has a consensus rating of Hold, which is based on 0 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Sangamo Therapeutics’s share price target?
            The average share price target for Sangamo Therapeutics is 1.76. This is based on 1 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €1.76 ,and the lowest forecast is €1.76. The average share price target represents 735.91% Increase from the current price of €0.21.
              What do analysts say about Sangamo Therapeutics?
              Sangamo Therapeutics’s analyst rating consensus is a Hold. This is based on the ratings of 1 Wall Streets Analysts.
                How can I buy shares of Sangamo Therapeutics?
                To buy shares of DE:GBY, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.